Phase I Clinical Study of RG7167 in Patients with Advanced Solid Tumors
Phase 1
- Conditions
- Advanced Solid Tumors
- Registration Number
- JPRN-jRCT2080221451
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Histologically or cytologically confirmed solid tumor
-Advanced cancer that did not respond to the standard therapy or for which a standard therapy has not been established
-PS of 0 to 2
Exclusion Criteria
-Patients in whom an adverse reaction to the previous treatment persists at Grade 2 or higher
-Patients with metastasis to the central nervous system that is accompanied by symptoms or requires treatment
-Clinically significant inflammatory condition is observed on the ocular surface
-Patients who have been treated with a drug targeting MEK in the past
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method